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Di(2-ethylhexyl) phthalate (DEHP) is an
aromatic diester used primarily to soften
and plasticize the rigid polymer polyvinyl chlo-
ride (PVC); DEHP may represent between
20 and 40% of the finished weight of the
plastic (Jaeger and Rubin 1973). Among
other properties, DEHP imparts to PVC ﬂexi-
bility, strength, optical clarity, and resistance
to broad-range temperature variations (Shea
2003). In its pure form, DEHP is a clear, oily
liquid, which is highly lipophilic (fat soluble)
and poorly soluble in water. In PVC plastic,
DEHP resides in the PVC matrix as a semisolid
and readily migrates out of the plastic into
blood or other lipid-containing solutions in
contact with the plastic, a phenomenon
observed with blood stored in PVC bags (Peck
and Albro 1982; Rock et al. 1984). Because of
its versatile properties, DEHP is also found in
many commercial and household products
such as vinyl ﬂoor and wall coverings, furniture,
raincoats, and shower curtains, as well as cos-
metics, personal care products, and food pack-
aging [Agency for Toxic Substances and
Disease Registry (ATSDR) 2002].
DEHP has been used as a plasticizer in
a variety of medical products, such as bags
containing blood, plasma, intravenous ﬂuids,
and total parenteral nutrition, tubing associated
with their administration, nasogastric tubes,
enteral feeding tubes, umbilical catheters, extra-
corporeal membrane oxygenation (ECMO) cir-
cuit tubing, hemodialysis tubing, respiratory
masks, endotracheal tubes, and examination
gloves. The rate of DEHP leaching varies not
only with the type of solution in contact with
the plastic material but also with storage and
temperatures at the time of use, storage time,
and percent DEHP in the plastic product
(Marcel 1973). The leaching rate of DEHP has
been studied most rigorously for banked blood
and plasma and, as reported, varies between
0.25 to 0.40 mg/100 mL/day for whole blood
stored > 21 days at 4°C and 6 mg/unit of
platelet concentrate stored at room temperature
(Jaeger and Rubin 1973; Marcel 1973; Peck
and Albro 1982). Leaching has also been
demonstrated in a study in which endotra-
cheal tubes were found to have 6–12% less
(0.06–0.12 mg DEHP/mg tube) DEHP after
use (Latini and Avery 1999).
Mono(2-ethylhexyl) phthalate (MEHP),
one of the metabolites of DEHP, consistently
produces developmental, reproductive, and
hepatic toxicity in laboratory animals (ATSDR
2002; Gray and Beamand 1984), raising con-
cern about whether human exposure to DEHP
approaches the levels of adverse effect found
in toxicologic studies. Medical devices contain-
ing DEHP are in extensive use in modern neo-
natal intensive care units (NICUs). It has been
estimated that such use might be exposing
infants to DEHP at levels that exceed the aver-
age daily adult exposure [median = 0.71 µg/kg
body weight/day (Kohn et al. 2000)] by
2–3 orders of magnitude, approaching the low-
est observed adverse effect level in animal stud-
ies (38–144 mg/kg body weight/day) (National
Toxicology Program 2000). A recent study
showed that MEHP urinary concentrations in
neonates undergoing intensive therapeutic
interventions in a NICU were several times
higher than those from the general U.S.
population (Calafat et al. 2004). In addition to
potentially high neonatal exposure in NICUs
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OBJECTIVE: Di(2-ethylhexyl) phthalate (DEHP) is a plasticizer used in medical products made with
polyvinyl chloride (PVC) plastic and may be toxic to humans. DEHP is lipophilic and binds non-
covalently to PVC, allowing it to leach from these products. Medical devices containing DEHP are
used extensively in neonatal intensive care units (NICUs). Among neonates in NICUs, we studied
exposure to DEHP-containing medical devices in relation to urinary levels of mono(2-ethylhexyl)
phthalate (MEHP), a metabolite of DEHP.
DESIGN: We used a cross-sectional design for this study.
PARTICIPANTS: We studied 54 neonates admitted to either of two level III hospital NICUs for at
least 3 days between 1 March and 30 April 2003.
MEASUREMENTS: A priori, we classiﬁed the infants’ exposures to DEHP based on medical products
used: The low-DEHP exposure group included infants receiving primarily bottle and/or gavage
feedings; the medium exposure group included infants receiving enteral feedings, intravenous
hyperalimentation, and/or nasal continuous positive airway pressure; and the high exposure group
included infants receiving umbilical vessel catheterization, endotracheal intubation, intravenous
hyperalimentation, and indwelling gavage tube. We measured MEHP in the infants’ urine using
automated solid-phase extraction/isotope dilution/high-performance liquid chromatography/
tandem mass spectrometry.
RESULTS: Urinary MEHP levels increased monotonically with DEHP exposure. For the low-,
medium-, and high-DEHP exposure groups, median (interquartile range) MEHP levels were
4 (18), 28 (58), and 86 ng/mL (150), respectively (p = 0.004). After adjustment for institution and
sex, urinary MEHP levels among infants in the high exposure group were 5.1 times those among
infants in the low exposure group (p = 0.03).
CONCLUSION: Intensive use of DEHP-containing medical devices in NICU infants results in higher
exposure to DEHP as reﬂected by elevated urinary levels of MEHP.
KEY WORDS: di(2-ethylhexyl) phthalate, hospital equipment and supplies, mono(2-ethylhexyl)
phthalate, neonatal intensive care units, newborn infants.
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tional concern regarding potential health risks
because, until 3 months of age, infants have
immature glucuronidation pathways. Because
glucuronidation, via enzymes such as UDP-
glucuronosyltransferase, facilitates urinary
excretion of phthalates and other xenobiotics, a
reduced potential for glucuronidation may lead
to slower MEHP excretion and higher levels of
MEHP in neonates than in older children and
adults (Leeder and Kearns 1997).
Among neonates in NICUs, we conducted
a study to characterize DEHP exposure and to
quantitatively relate the use of DEHP-con-
taining products to urinary levels of MEHP, a
biologic marker of DEHP exposure.
Materials and Methods
Study population. We studied a convenience
sample of 54 infants enrolled from the level
III NICUs at two major Boston-area hospi-
tals. Level III NICUs provide all newborn
care, including mechanical ventilation, high-
frequency ventilation, surgery, and cardiac
catheterization. We selected infants to reﬂect
a range of diagnoses (including congenital
anomalies and developmental and metabolic
abnormalities) and NICU care requirements
(including ventilation, enteral feedings, par-
enteral nutrition, and indwelling catheteriza-
tion). Infants must have been in the NICU at
least 3 consecutive days before enrollment, have
had a corrected gestational age of ≤ 44 weeks,
and have been born at or transferred to either
hospital between 1 March and 30 April 2003.
Concerns regarding the sensitivity of this
research led to the design and implementa-
tion of a data and sample collection protocol
that was based on visual inspection and that
did not include inspection of the medical
records. The study protocol and methods were
approved by the institutional review boards of
Harvard School of Public Health, Brigham
and Women’s Hospital, and Massachusetts
General Hospital.
Assessment of DEHP exposure. Before
data collection, we defined three DEHP
exposure categories (low, medium, and high)
based on a review of medical products typi-
cally used in both NICUs and information
provided by their manufacturers with respect
to DEHP content. Infants classiﬁed as having
low DEHP exposure were those receiving pri-
marily bottle and/or gavage feedings. The
medium-DEHP exposure group included
infants receiving enteral feedings by indwelling
gavage tubes either continuously or by bolus
feedings; intravenous hyperalimentation by
indwelling percutaneous intravenous central
catheter (PICC) line, broviac, or umbilical
vessel catheter (UVC); and/or nasal continu-
ous positive airway pressure by nasal prongs.
The high-DEHP exposure group included
infants receiving continuous indwelling UVC,
endotracheal intubation, intravenous hyper-
alimentation by the central venous route (i.e.,
PICC line, broviac, UVC), and an indwelling
gavage tube (for gastric decompression).
One of the study investigators (R.G.)
observed the care of each infant for 1–4 hr
per day for 1–3 days per infant, for a total of
3–12 hr of observation per infant. Observations
were made during a single day for 37 infants,
on 2 days for 12 infants, and on 3 days for
5 infants. During the observations, the investi-
gator took an inventory of products in use for
the care of each infant. This information was
used to categorize infants into low-, medium-,
and high-DEHP exposure groups. None of the
infants changed DEHP exposure groups over
the course of observation.
Assessment of urinary MEHP. The observ-
ing investigator collected spot urine samples at
the end of each infant’s observation period(s).
A total of 81 urine samples were collected
from 54 infants. Two or more urine samples
came from 17 infants, and of these, four sam-
ples were collected concurrently with the ﬁrst
samples, and 18 others were collected 6–72 hr
after the ﬁrst samples. We used these repeated
samples to assess intraindividual variability in
urinary MEHP levels.
Urine samples were collected by either
squeezing the urine from a cotton gauze
placed in the infant’s diaper at the beginning
of the observation period or from the cotton
ﬁlling of the diaper the infant wore during the
period of observation. The cotton gauze or
the removed cotton diaper ﬁlling was placed
into a 3–5 cc polypropylene syringe (Becton-
Dickinson, Franklin Lakes, NJ), the plunger
was replaced, and the urine was squeezed into
a 2- or 4-cc Nunc (Rochester, NY) cryovial.
Urine samples were frozen within 4–6 hr at
–35°C and shipped on dry ice to the Centers
for Disease Control and Prevention (CDC;
Atlanta, GA) for analysis.
Urine specimens were analyzed for
10 phthalate monoesters, including three
DEHP metabolites [MEHP, mono(2-ethyl-5-
hydroxyhexyl) phthalate, and mono(2-ethyl-5-
oxohexyl) phthalate], using automated solid-
phase extraction/isotope dilution/high-perfor-
mance liquid chromatography/tandem mass
spectrometry at the CDC. Monobutyl phtha-
late and monobenzyl phthalate were also fre-
quently detected. In this report, we focus on
levels of MEHP, because this metabolite has
been most studied and is a valid biomarker of
DEHP exposure.
The analytical method used for measuring
phthalate metabolites in urine has been
described in detail previously (Silva et al. 2004).
Briefly, the method involved the enzymatic
deconjugation of the phthalate metabolites
from their glucuronidated form, followed
by automated solid-phase extraction. We
used reversed-phase high-performance liquid
chromatography to separate the phthalate
metabolites from other components in the
extracted urine. We then quantified the
metabolites by isotope dilution/tandem mass
spectrometry. Samples, reagent blanks, and
quality control (QC) materials were processed
identically. QC materials were analyzed along
with the study samples to ensure the accuracy
and reliability of the data. QC materials with
low concentrations (QCL) and high concen-
trations (QCH) were prepared from a base
urine pool, obtained from multiple anonymous
donors as described previously (Silva et al.
2004), dispensed in 5-mL aliquots, and stored
at –20°C. Each QC material was characterized
by repeated measurements, spanned over sev-
eral weeks, to deﬁne the mean concentrations
and the 95% and 99% control limits of
MEHP. Each analytical run consisted of 50
(5 QCs, 5 blanks, and 40 unknown) samples.
The concentrations of the replicate QCH and
QCL materials, averaged to obtain one meas-
urement of QCH and QCL for each run, were
evaluated using standard statistical probability
rules. All MEHP concentrations, reported in
nanograms per milliliter of urine, were blank-
corrected. However, MEHP is not typically
found in the reagent blank samples, and when
it is, it is at concentrations near the limit of
detection (LOD; 0.87 ng/mL). Specimens with
MEHP levels below the LOD were assigned a
value of 0.435 ng/mL, the midpoint between 0
and the LOD.
Assessment of other variables. We collected
data, as available, on gestational age and length
of stay in the NICU. However, data on these
variables were incomplete for about half of the
infants because, as noted, the sample collection
was anonymous and not based on review of
medical records. The interpretation of these data
is likely to be tenuous because of missing data,
and we therefore do not present these results.
Statistical analysis. We used Fisher’s exact
test to evaluate differences in sex and institution
by DEHP exposure group. To evaluate the
intraindividual variability of urinary MEHP
levels, we computed Spearman correlations
between repeated urine specimens. For unad-
justed comparisons of urinary MEHP levels by
sex, institution, and DEHP exposure group, we
used the Mann-Whitney Kruskal-Wallis non-
parametric test. We used multiple linear regres-
sion to compare urinary MEHP levels across
DEHP exposure groups, adjusting for institu-
tion and infants’ sex. Because the distribution
of urinary MEHP was skewed, we used log-
transformed MEHP values in the regression
models. In regression models of log-transformed
MEHP, the regression parameters estimated
MEHP levels in the medium- and high-DEHP
exposure groups as a proportion of MEHP lev-
els in the low-DEHP exposure group. Our pri-
mary analyses focused on the MEHP levels in
the first urine specimen collected from each
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DEHP-containing medical products and urinary levels of MEHPinfant; in secondary analyses, we incorporated
ﬁrst and, where available, second and third spec-
imens, using repeated-measures regression to
compare MEHP levels across exposure groups.
We used quantile regression (Koenker and
Hallock 2001) to estimate sex- and institution-
adjusted quartiles of urinary MEHP for each
DEHP exposure group.
Results
The 54 infants in our study were roughly
equally distributed between the two institutions,
and 34 (63%) were female (Table 1). Thirteen
(24%) infants had low exposure to DEHP-
containing products, 24 (44%) had medium
exposure, and 17 (32%) had high exposure.
Among the ﬁrst set of urine samples collected
from these infants, 11 (20%) had MEHP levels
that were less than the LOD (0.87 ng/mL), and
the maximum level was 758 ng/mL (geometric
mean = 14 ng/mL; geometric SD = 8.6 ng/mL).
Correlation between urinary MEHP
levels in repeated urine samples. Among the
17 infants with multiple urine samples, urinary
MEHP measurements from the same infants
were highly correlated. Spearman correlations
were 0.9 (p < 0.0001; n = 17) for urinary
MEHP levels in the first and second urine
specimens, 0.9 (p = 0.04; n = 5) for the second
and third specimens, and 0.7 (p = 0.2; n = 5)
for the ﬁrst and third specimens. Although our
data were limited, we observed no apparent
dissimilarity in the correlation between speci-
mens collected at the same time (correlation
coefficient r = 0.80; n = 4) versus those col-
lected at different times (r = 0.88; n = 13 ﬁrst
and second samples only).
Correlates of DEHP exposure group and
urinary MEHP. Compared with infants in the
two lowest DEHP exposure groups, infants in
the high-DEHP exposure group were more
likely to be patients at institution B (Table 1).
In unadjusted comparisons, urinary MEHP
levels were signiﬁcantly higher among infants
at institution B (Mann-Whitney Kruskal-
Wallis p = 0.002; Table 2).
Association of DEHP exposure group with
urinary MEHP. Progressively higher DEHP
exposure group was associated with progres-
sively higher urinary MEHP levels. Median
urinary MEHP levels (and 25th and 75th per-
centiles) in infants in the low-, medium-, and
high-DEHP exposure groups were 4 (< LOD,
18), 28 (3, 61), and 86 (21, 171) ng/mL,
respectively. DEHP exposure group remained
a substantial predictor of urinary MEHP levels
even after adjusting for infants’ sex and insti-
tution of hospitalization (p = 0.09; Table 3,
Figure 1). Compared with infants in the
low-DEHP exposure group, infants in the
medium-DEHP exposure group had urinary
MEHP levels that were twice as high [95%
conﬁdence interval (CI) of the multiplication
factor, 0.5–7.4; p = 0.3], and infants in the
high-DEHP exposure group had levels that
were 5.1 times as high (95% CI of the multi-
plication factor, 1.2–21.9; p = 0.03). These
results were identical when we analyzed all
ﬁrst, second, and third urinary MEHP values
together using repeated-measures regression.
Urinary creatinine levels were available for
67 samples, 45 infants in total. Using this
restricted sample, we analyzed the association
between DEHP exposure group and creati-
nine-adjusted urinary MEHP concentrations,
and the results were nearly identical to the
results from the analyses of unadjusted MEHP
levels.
Discussion
Our study of 54 infants receiving care in two
NICUs demonstrated that the use of DEHP-
containing medical devices is associated with
a monotonic increase in urinary levels of
MEHP, a metabolite of DEHP. In particular,
Green et al.
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Table 2. Median concentrations (and 25th and 75th percentiles) of urinary MEHP, by sex, institution, and
DEHP exposure group.
Urinary MEHP level (ng/mL)
Factor 25th percentile Median 75th percentile p-Valuea
Sex 0.15
Female 3 20 64
Male 19 39 75
Institution 0.002
A < LODb 12 29
B1 8 5 8 9 2
DEHP exposure group 0.001
Low < LODb 41 8
Medium 3 28 61
High 21 86 171
aMann-Whitney Kruskal-Wallis nonparametric test to evaluate differences in urinary MEHP distribution. bLOD = 0.87 ng/mL.
Table 3. Relativea urinary MEHP levels (95% CIs), by DEHP exposure group, as a multiple of urinary MEHP
in the low-DEHP exposure group (referent = low).
Adjusted for Adjusted for sex
DEHP exposure group Not adjusted Adjusted for sex institution and institution
Low 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
Medium 3.4 (0.9–13.4) 3.1 (0.8–11.2) 2.2 (0.6–8.6) 2.0 (0.5–7.4)
High 12.4 (2.9–53.1) 9.7 (2.4–39.5) 6.1 (1.3–28.2) 5.1 (1.2–21.9)
Test of overall differences 0.0004 0.008 0.06 0.09
among groups, p-value
aEstimates are multiplication factors derived from regression models of log-transformed urinary MEHP. They compare uri-
nary MEHP levels in the medium- and high-DEHP exposure groups with levels in the low-DEHP exposure group. For
example, after adjusting for sex and institution, urinary MEHP levels in the high-DEHP exposure group were about
5.1 times as great as those in the low-DEHP exposure group (95% CI, 1.2–21.9 times as great).
Figure 1. Median and interquartile range of urinary
MEHP, by DEHP exposure group, and adjusted for
institution and infant sex using quantile regression.
Low Medium High
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
U
r
i
n
a
r
y
 
M
E
H
P
 
(
n
g
/
m
L
)
DEHP exposure group
75th percentile
25th percentile
median
89
40
25
Table 1. Characteristics, by DEHP exposure group [n (%)].
DEHP exposure group
Factor No. Low (n = 13) Medium (n = 24) High (n = 17) p-Valuea
Sex > 0.9b
Female 34 8 (62) 15 (63) 11 (65)
Male 18 4 (31) 8 (33) 6 (35)
Missing 2 1 (8) 1 (4) 0 (0)
Institution 0.01
A 28 11 (85) 12 (50) 5 (29)
B 26 2 (15) 12 (50) 12 (71)
aFisher’s exact test comparing the distribution of sex and institution, respectively, across DEHP exposure group.
bExcludes infants with missing data on sex.Environmental Health Perspectives • VOLUME 113 | NUMBER 9 | September 2005 1225
urinary MEHP levels among infants in the
high-DEHP exposure group were ﬁve times as
high as those in the low-DEHP exposure
group, after adjustment for infants’ sex and
institution of care. Urinary MEHP levels
among infants in the medium-DEHP expo-
sure group were twice as high as levels among
infants in the low-DEHP exposure group.
Adjustment for institution resulted in modest
attenuation in the association between DEHP
exposure group and urinary MEHP, which
may reflect the potential influence of other
unmeasured sources of DEHP exposure that
differed between institutions. In addition,
urinary MEHP levels were modestly higher
among male infants. Although the length of
observation varied across infants, because of
the acuteness of care requirements and the
indwelling (and therefore continuous) nature
of many of the products used, potential DEHP
exposure from medical devices in use was sta-
ble over each infant’s observation period(s).
To date, there are limited measurements
on human neonatal exposures to phthalates
(Calafat et al. 2004) and, to our knowledge,
no data on whether such exposures are asso-
ciated with adverse health effects in these
neonates. Limited data describe the effects
of neonatal exposures on health later in life.
A study of 18 adolescents 14–16 years of age
who had undergone ECMO as neonates found
no apparent abnormalities in their growth and
pubertal maturity, and the levels of luteinizing
hormone, follicle-stimulating hormone, testos-
terone (in boys), and estradiol (in girls) were
within the normal reference ranges for stage
of pubertal development (Rais-Bahrami et al.
2004). It is difficult to draw definitive con-
clusions from this study, because it was very
small, and normal reference ranges for repro-
ductive hormones, physical growth, and sex-
ual maturation are quite wide. Furthermore,
the postnatal levels of DEHP or its metabo-
lites at the time of the ECMO treatment were
not known.
Our study is limited by the narrow range
of descriptive data available on the infants and
the small number of infants examined. Yet it is
the ﬁrst study to directly examine the relative
use of DEHP-containing medical products
among NICU infants in relation to urinary
MEHP concentration. Because our study
included infants with a range of diagnoses and
NICU care requirements, the results of this
research may be generalizable to infants of
other level III NICUs.
Several studies have considered DEHP
exposure or sources of DEHP exposure in
NICU infants (Calafat et al. 2004; Karle et al.
1997; Latini and Avery 1999; Loff et al.
2000). Calafat et al. (2004) considered expo-
sure to DEHP from medical procedures in
six newborn infants of a university hospital
NICU undergoing intravenous infusion for
more than 2 weeks. The geometric mean level
of MEHP (100 ng/mL) in 33 urine samples
collected from these children was several
times higher than that from the general U.S.
population ≥ 6 years of age (geometric mean,
3.43 ng/mL) (CDC 2003). The urinary
MEHP levels reported in that study were sim-
ilar to those in the high-DEHP exposure
group in our study. Brock et al. (2002) stud-
ied 19 toddlers 12–17 months of age in
Imperial County, California. Twelve children
provided two urine samples, and seven chil-
dren provided a single sample. Eight urine
samples from six children had detectable
levels of MEHP. The mean urinary MEHP
level was 4.6 ng/mL (SD, 6.4 ng/mL; range,
LOD < 1.2 to 47.3). These levels were an
order of magnitude lower than the mean in
the present study on neonates.
Others have directly assessed sources of
DEHP exposure from medical devices among
infants. Among neonates, Karle et al. (1997)
found that DEHP leached from ECMO
circuit tubing at 10.5–34.9 mg/kg, depending
on length, type, and size of PVC tubing.
Interestingly, circuits with heparin coating
did not leach DEHP. Latini and Avery
(1999) directly observed the degradation of
44 indwelling PVC endotracheal tubes that
had been used in NICU infants for as little as
12 hr. These tubes demonstrated a substantial
loss of DEHP, 0.06–0.12 mg DEHP per mg
of sample (6–12%), compared with unused
tubes.
In our study, DEHP exposure differed
signiﬁcantly by institution. Speciﬁcally, most
high-DEHP-exposure infants were from insti-
tution B, and infants from institution B had a
greater median urinary MEHP concentration
than did infants from institution A. Loff et al.
(2000) studied DEHP leaching from par-
enteral nutrition infusion lines used for 24-hr
fat emulsion administration in 2-kg neonates
and found that 25 mL of standard 20% lipid
emulsion administered by pump via polyeth-
ylene syringes and PVC infusion line yielded
samples (after 24 hr at 27°C) having postinfu-
sion DEHP concentrations of 422.8 µg/mL.
The authors concluded that the total amount
of DEHP for a 2-kg baby caused by lipid
emulsions in a day, under these conditions, is
approximately 10.2 mg. In our study, we
speculate that the higher exposure to DEHP
in institution B compared with institution A
reﬂects the extensive use in particular of two
DEHP-containing items at institution B:
unsiliconized PVC indwelling endotracheal
tubes, and a PVC indwelling hemodynamic
monitoring UVC used for, among other
things, parenteral nutrition. These DEHP-
containing medical devices were sparingly
used in institution A.
In conclusion, our study demonstrated
an association between the use of DEHP-
containing medical products and urinary levels
of MEHP in NICU infants. This study was
designed to evaluate the distribution of expo-
sure to DEHP among NICU neonates only.
Additional studies, larger and more compre-
hensive than the present one, with follow-up
of the infants, are needed. Such studies would
help determine potential health risks, if any,
from DEHP exposure among NICU infants.
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